NCT03373071View on ClinicalTrials.gov

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 23, 2017

Primary Completion Date

May 11, 2021

Study Completion Date

January 24, 2025

Conditions
CD19-ALLCD19-LNH
Interventions
BIOLOGICAL

CD19-CAR T cell

"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"

Trial Locations (1)

Unknown

Ospedale Pediatrico Bambino Gesù, Roma

All Listed Sponsors
lead

Bambino Gesù Hospital and Research Institute

OTHER

NCT03373071 - Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL | Biotech Hunter | Biotech Hunter